Macaulay, Valentine MValentine MMacaulayLord, SimonSimonLordHussain, SyedSyedHussainMaroto, José PabloJosé PabloMarotoJones, Robert HughRobert HughJonesCliment, Miguel ÁngelMiguel ÁngelClimentCook, NatalieNatalieCookCHIA-CHI LINWang, Shian-ShiangShian-ShiangWangBianchini, DilettaDilettaBianchiniBailey, MarkMarkBaileySchlieker, LauraLauraSchliekerBogenrieder, ThomasThomasBogenriederde Bono, JohannJohannde Bono2024-01-122024-01-122023-1000070920https://scholars.lib.ntu.edu.tw/handle/123456789/638439This multicentre, open-label, Phase Ib/II trial evaluated the insulin-like growth factor (IGF) 1/2 neutralising antibody xentuzumab plus enzalutamide in metastatic castrate-resistant prostate cancer (mCRPC).en[SDGs]SDG3journal article10.1038/s41416-023-02380-1375372532-s2.0-85166616702https://api.elsevier.com/content/abstract/scopus_id/85166616702